WuXi Biologics has reported impressive growth figures for the first half of 2026, showcasing its resilience and strategic advancements in the biotechnology sector. The company’s revenue reached RMB 11.8 billion, marking an 18.4% increase year-on-year, which translates to a 23.4% growth when measured in USD.
Financial Performance Highlights
The financial results reflect significant operational efficiency, with the IFRS gross profit margin expanding to 46.2%, an increase of 350 basis points compared to the previous year. The adjusted gross profit margin also grew to 48.4%, up by 280 basis points, despite facing challenges from foreign exchange fluctuations.
EBITDA experienced a modest growth of 3.5% year-on-year, reaching RMB 4.4 billion, while the IFRS net profit rose by 5.8% to RMB 2.9 billion. In contrast, adjusted EBITDA surged by 24.9% to RMB 5.4 billion, and adjusted net profit saw a remarkable increase of 38.6%, totaling RMB 3.9 billion.
Earnings and Cash Flow
Earnings per share (EPS) also reflected positive trends, increasing by 3.4% to RMB 0.60. Adjusted EPS soared by 37.3%, reaching RMB 0.81. Free cash flow reached RMB 1.5 billion during the reporting period, maintaining a positive trajectory for five consecutive years.
The total backlog climbed to an impressive US$25.1 billion, with a notable increase of approximately 30% year-on-year in the backlog expected within three years, now totaling US$5.5 billion. This growth underscores the robust demand for WuXi’s services.
Project Expansion and Innovations
In H1 2026, WuXi Biologics added a record 123 new organic integrated projects, a 43% increase compared to the previous year. Of these, 70% focused on complex biologics modalities. Additionally, the acquisition of BioDlink by WuXi XDC contributed 46 integrated projects, bringing the total to 1,064.
The company’s “Win-the-Molecule” strategy continues to gain momentum, with 16 post-IND wins in the first half of 2026, including several projects in advanced stages of development. Cumulatively, there are now 128 Win-the-Molecule projects since its inception in 2018.
Regulatory and Capacity Developments
WuXi Biologics supported 68 IND filings in H1 2026 and aims to expand its annual filing capacity to 300 by 2027. The company has also scheduled 34 PPQs for 2026 and an additional 30 for 2027, maintaining a flawless success rate for PPQ campaigns thus far.
The company is actively expanding its manufacturing capabilities across multiple regions. New facilities are being developed in Shanghai, Chengdu, Hangzhou, and the U.S., enhancing global supply chain resilience and capacity to meet increasing commercial demands.
Technological Advancements and Sustainability
WuXia™ TrueSite, a new platform launched in October 2025, has been incorporated into over 70 projects. This technology accelerates development timelines and enhances productivity, making it a key asset for WuXi’s competitive edge, particularly in biosimilar programs.
Sustainability remains a cornerstone of WuXi’s strategy, with ongoing recognition from global ESG rating agencies for its environmental practices. The company is committed to integrating sustainable practices throughout its operations and value chain.
Leadership Insights
Dr. Chris Chen, CEO of WuXi Biologics, emphasized the company’s strong growth in the first half of 2026, driven by increased demand and operational efficiencies. He highlighted the importance of technology differentiation and stated that WuXia™ TrueSite is expected to enhance both the Follow-the-Molecule and Win-the-Molecule strategies.
Dr. Ge Li, Chairman of WuXi Biologics, echoed these sentiments, underscoring the strength of the integrated CRDMO platform and the long-term value of investments in technology and quality. He reaffirmed the company’s commitment to supporting global partners with innovative solutions.
Looking Ahead
WuXi Biologics is well-positioned for future growth, with visibility into its manufacturing expansion bolstered by a strong pipeline and strategic investments. The company remains committed to optimizing its business portfolio in response to market demands while focusing on technological advancements that will drive long-term value for clients and stakeholders.
In conclusion, WuXi Biologics has demonstrated remarkable resilience and strategic foresight in the evolving biotechnology landscape. Its strong financial performance, coupled with innovative project additions and a commitment to sustainability, positions the company for continued success in the coming years.
- Key Takeaways:
- Revenue growth of 18.4% YoY, reaching RMB 11.8 billion.
- Significant backlog increase, providing strong revenue visibility.
- Record number of new integrated projects, focusing on complex biologics.
- Commitment to sustainability and innovation in technology.
- Ongoing expansion of manufacturing capabilities globally.
Read more → finance.yahoo.com